A nnually, about 16 million first-ever strokes occur worldwide, with a death toll of approximately 5.7 million people per year. 1 In addition, stroke is the major cause of morbidity among adults, with up to half of all patients who survive after the stroke failing to regain independence and needing long-term health care. 2 Angiotensin-converting enzyme inhibitors (ACEIs) have shown promising effects in reducing the incidence of ischemic stroke in populations at risk 3 and in alleviating ischemic stroke severity and improving its outcomes. 4, 5 Although their main effect is on hypertension treatment, the main modifiable vascular risk factor for ischemic stroke, previous evidence has shown that these drugs can decrease the severity of ischemic stroke by other mechanisms including neuroprotective properties, beneficial properties on the endothelium, and an antiatherosclerotic effect. 3, 6 Antiplatelets (APs) have been prescribed for secondary ischemic stroke prevention 7 and are increasingly being prescribed for primary prevention since their effectiveness for primary stroke prevention is still uncertain. 8 Several studies have evaluated the role of APs, mainly aspirin, in reducing stroke severity and therefore enhancing outcome. These studies have shown conflicting results, with some finding a positive effect of AP use, 9, 10 whereas others have found that previous AP use has no significant effect on stroke severity. 11, 12 Moreover, statins are widely used for the treatment of dyslipidemia and secondary prevention in patients with ischemic heart disease (IHD). These agents have been proven to significantly reduce the risk of ischemic stroke in populations at risk 13 and improve stroke-related mortality and outcomes. 14, 15 Does previous combination therapy of ACEI with AP and/or statin have an additive effect compared with ACEI therapy alone in improving the functional outcome of ischemic stroke patients as measured by the Barthel Index (BI)? To the best of our knowledge, none of the studies performed to date have taken into account the comparison between previous ACEI-only use and its combination with AP and/or statin on ischemic stroke outcome at discharge. We performed this observational study to evaluate the impact of ACEI alone versus combination of ACEI with AP and/or statin on BI scores at discharge and to identify the factors associated with improving functional outcome of ischemic stroke patients, including demographic, risk, and clinical factors in addition to previous medications.
MATERIALS AND METHODS

Patients, Setting, and Study Design
We retrospectively reviewed the collected acute ischemic stroke data of patients admitted to a 1200-bed hospital located in northern Malaysia over the year period of 2008. Before starting the study, permission for the use of patient clinical information was obtained from the local health authorities and medical ethics committee.
The study patients were identified according to the International Classification of Diseases, 10th Revision. Using a computergenerated list obtained from the hospital record office, patients with diagnostic codes I63.0 to I63.9 (acute ischemic stroke) were included in the study. Case verification was supplemented by records from medical wards and the intensive care unit. Data were gathered from medical records, in which physicians and neurology specialists documented the medical history, sociodemographic and clinical characteristics, previous medication use, ongoing management, and any action taken or any change in health status of the patients from admission until discharge. In a special form, the ward pharmacists also recorded the medications and their dosages and any allergies or problems arising from medications that were taken by the patient before hospitalization. In addition, the nurses documented the vital signs and any action taken or any change in patient health status from admission until discharge. Another special form for recording the BI score was filled out by the occupational therapist or the physiotherapist and the physician. The information in these forms was the main source of retrospective data for the present study. In addition to the medical records, further prospectively compiled and maintained registries were accessed for the express purpose of gaining retrospective data, to manage any missing entries that may be found and to confirm the data recorded in the patients' medical files. These records are stroke notification forms for the National Neurology Registry in which important information related to ischemic stroke patients was recorded.
Demographic Data, Risk Factors, and Clinical Characteristics
Demographic data and risk factors were retrieved for each patient. The main risk factors included hypertension, diabetes mellitus (DM), dyslipidemia, IHD, atrial fibrillation (AF), renal impairment, heart failure, and previous stroke or transient ischemic stroke attack. The presence of these diseases was checked from the patients' medical records. In addition, risk factors and comorbidities were defined by the medical staff dealing with the ischemic stroke patients and verified by the researcher as follows: Hypertension was defined as systolic blood pressure of greater than 140 mm Hg or diastolic blood pressure of greater than 90 mm Hg, a physician's diagnosis of hypertension, or when a patient was on an antihypertensive therapy. 16 Diabetes mellitus was determined based on the concentration of fasting blood glucose being greater than 6.3 mmol/L or a history of diet-controlled, oral hypoglycemic-treated, or insulintreated disease. 17 Dyslipidemia was defined as elevated lowdensity lipoprotein (9130 mg/dL) or triglycerides (9150 mg/dL) or decreased high-density lipoprotein (G40 mg/dL). 18 A previous history of AF was noted in addition to screening for AF by the hospital physician from an electrocardiography performed either during the patient's hospital stay or from previous evaluation. Ischemic heart disease was defined as a history of angina or myocardial infarction. 19 Serum creatinine concentrations of 2 mg/dL or greater or at least 50% higher than baseline were selected as indicators of renal impairment. 20 Acute ischemic stroke was categorized according to the Oxfordshire Community Stroke Project (OCSP) classification system; this classification depends on the signs and symptoms present at the time of maximal deficit after the stroke attack and is determined without the reference to brain imaging findings. Also, this classification can predict the fatality and functional recovery after the attack. 21 This classification includes total anterior circulation infarct (TACI), partial anterior circulation infarct, lacunar infarct (LACI), posterior circulation infarct (POCI), and unclassified type. 22 The Glasgow Coma Scale (GCS) was measured on admission and used to assess the level of consciousness of the ischemic stroke patients. The GCS is composed of independent observations of 3 aspects of behavior of eye opening and motor and verbal responsiveness with a scale ranging from 3 (most severe cases) to 15 (highly conscious cases). In our study, the GCS was divided into 3 categories: minor (total score Q13), moderate (total score 9Y12), and severe (total score e8).
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Previous Pharmacological Classes
All medications that were taken before the current stroke and the main medications used during hospitalization that may affect the functional outcomes at discharge were assessed.
In the current study, previous use of ACEI, AP, and statin were noted with particular attention. In addition, for better evaluation of the impact of the use of ACEI alone or combined with AP and/or statin on the functional outcome, for better comparison among these groups, and for the control of any confounding protective effects of AP and statin used alone before hospitalization, patients who used AP alone, statin alone, or AP + statin before the current attack were excluded. 24 Moreover, patients discharged against medical advice, patients without a measured BI score, and those who were referred to another hospital were excluded. In addition, in evaluating the impact of ACEI alone versus combination of ACEI with AP and/or statin on BI scores at discharge, patients who did not take any of these preventive medications before the attack were excluded from the sample in this analysis only.
As few patients were on angiotensin II receptor blockers, and none of them were on ACEI, these patients were all considered as ACEI-treated patients for purposes of statistical analysis.
Outcomes
The BI is valid, reliable, and one of the most frequently used scoring tools for assessing the functional status and the activities of daily living of stroke patients. 25, 26 The total BI is a cumulative score of the 10 items of varying weights that are related to selfcare and mobility, with a maximum score of 100 corresponding to complete independence, and a minimum score of 0 representing a total dependent bedridden state. A score of 100 does not necessarily mean normality, but only that the patient should manage without assisted care. The results of patients who died were assigned with the lowest possible score (0) in the BI.
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In addition, higher number of previous clinical and observational studies evaluated the functional outcome of stroke patients using the BI that was dichotomized at a high sensitivity and specificity cutoff point of 75.
11,27Y35 In the current study, a score of 75 or more was defined as a good functional status with mild or no dependency on essential personal care, such as moving around unassisted, eating, sphincter control, and personal toileting.
Statistical Analysis
Data were analyzed using the Statistical Package for Social Sciences program version 15 (SPSS Inc, Chicago, Ill). Categorical variables were expressed as frequency (%) and mean (SD) for continuous variables. The included patients were categorized into good and poor functional outcome groups; univariate statistics were used to determine the relationships between demographic, risk factors, clinical characteristics, and previous medication with a functional outcome score at discharge.
After excluding the patients who did not take any preventive medication before the attack, we grouped the patients into 4 groups: those who were taking ACEI alone before their stroke, those who were taking ACEI + AP, those who were taking ACEI + statin, and those who were taking all 3 classes of these drugs (ACEI + AP + statin). We used univariate analysis to study the impact of ACEI alone versus the other combinations of ACEI on functional outcomes after using ACEI alone as the reference for the combinations.
The W 2 or Fisher exact tests were used, as appropriate, to test for significance between categorical variables. An independent Student t test was used to compare the means of continuous variables. P G 0.05 was considered significant.
Multiple logistic regression was used to assess the factors associated with a good outcome on the BI scale. Variables included in the regression were those with significant P values (G0.05) in the univariate analysis. In addition, the independent impact of previous treatment with ACEI on having a good outcome on BI was determined while simultaneously controlling for the possible effects of the candidate confounding factors and their potential interactions with ACEI use. The proportion of patients being discharged with a good outcome was expressed as a prevalence rate with a 95% confidence interval (95% CI). The association between patients discharged with good outcomes and the variables of interest was evaluated by calculating the odds ratio (OR) with the corresponding 95% CI.
RESULTS
Patient Characteristics, Risk Factors, and Clinical Characteristics
Six hundred fifty-one patients with a diagnosis of acute ischemic stroke were admitted during the study period. Among these, we excluded 99 patients who were on AP alone, statin alone, or AP + statin before the current attack. Moreover, 17 patients discharged against medical advice, 16 patients without a measured BI score, and 14 referred to another hospital were excluded. Therefore, 505 patients met the study inclusion criteria. Table 1 summarizes the demographic and clinical characteristics of patients according to the functional outcome at discharge as measured by BI. The patients' mean age was 64.5 (SD, 12.5) years, and 299 (59.2%) were male. Chinese patients represented 275 (54.4%) of the study population, followed by Malays 147 (29.1%) and Indians 74 (14.7%). Other ethnic groups consisted of foreigners mainly from other neighboring Asian countries.
Of the 505 patients, 257 (50.8%) had a good outcome as measured by the BI score at discharge. From Table 1 , univariate analysis showed that patients with good functional outcome at discharge were significantly younger (P G 0.001) and male (P = 0.002). In addition, patients discharged with better outcome (BI Q 75) were less likely to have had a prior stroke or transient ischemic attack (P = 0.013). The 2 groups of good and poor outcome were comparable in risk factors such as hypertension, DM, dyslipidemia, IHD, and heart failure, with the exception of patients having AF (P = 0.036) or renal impairment (P = 0.010) who had significantly poor outcomes at time of discharge.
Based on ischemic stroke classification on admission, patients with a diagnosis of TACI ischemic stroke were more likely to be discharged with poor outcome, whereas patients with a diagnosis of LACI or POCI were more likely to be discharged with better outcome (P G 0.001). In addition, patients admitted with moderate or severe GCS score had a significantly higher
TABLE 2. Comparison of Good and Poor Outcome According to BI Classification Between Various Treatment Groups
Variable Total (n = 505) , n (%) BI Q75 (n = 257) , n (%) BI G75 (n = 248), n (%) P risk of having poor outcome at discharge compared with patients with minor GCS score (P G 0.001). Table 2 illustrates different pharmacological agents used before and during hospitalization. The proportion of patients treated with anticoagulants before stroke or during hospitalization or with previous other antihypertensive drugs other than ACEI were comparable between the good and poor outcome groups.
Pharmacological Agents Used and Outcome
One hundred twenty patients (46.7%) discharged with good outcome were on previous ACEI either alone or with AP and/or statin compared with 78 patients (31.5%) discharged with poor outcome and were on the same medication classes before the attack (P G 0.001).
To study the impact of ACEI alone versus combination of ACEI with AP and/or statin on the BI score at discharge, 307 patients who did not take ACEI alone, ACEI + AP, ACEI + statin, or ACEI + AP + statin before the attack were excluded. Among the remaining 198 patients, 62 (31.3%) were on ACEI alone before stroke onset, 27 (13.6%) were taking an ACEI + AP, 29 (14.7%) were taking an ACEI + statin, and 80 (40.4%) were taking all 3 classes of drugs before the current attack.
For functional outcome at discharge as measured by BI scores, there were no significant differences among ACEI combination classes (P = 0.852). Using ACEI alone as the reference for ACEI + AP, ACEI + statin, or ACEI + AP + statin combinations, results from the univariate analysis demonstrated no significant benefits of adding AP and/or statin to ACEI on functional outcome at discharge compared with ACEI alone.
The multiple logistic regression analysis of variables associated with good functional outcome is shown in Table 3 . The results showed that the incidence of patients being discharged with good outcome increased by 3% (95% CI, 0.96Y0.99) for each 1-year decrease in age (P = 0.002). The odds of occurrence of good functional outcome were higher in the first-ever stroke cases, with an OR of 1.86 (95% CI, 1.12-3.07; P = 0.016) as compared with those with recurrent stroke attacks.
Regarding ischemic stroke OCSP classification and by using TACI as a reference class, patients with a diagnosis of LACI (OR, 13.26; 95% CI, 1.65Y25.72; P = 0.015) or POCI (OR, 10.39; 95% CI, 1.19Y20.18; P = 0.034) were discharged with a significantly better outcome. Moreover, minor GCS score was an independent predictor of good outcome at discharge. On the contrary, moderate and severe GCS scores were independently associated with poor outcome (OR, 0.32; 95% CI, 0.17Y0.59; P G 0.001; and OR, 0.09; 95% CI, 0.03Y0.27; P G 0.001, respectively).
With regard to previous medication use, being on ACEI either alone or combined with AP and/or statin showed a significant positive association with increasing the BI score at discharge. Being on ACEI (OR, 2; 95% CI, 1.28Y3.11; P = 0.002) before the current stroke attack significantly enhanced the functional outcome at discharge. Moreover, even after controlling for confounding factors with logistic regression, previous use of ACEI (P = 0.002) still significantly enhanced the functional outcome at discharge as measured by the BI score.
DISCUSSION
A differential effect of ACEI alone on functional outcome at discharge in comparison with ACEI + AP, ACEI + statin, or the combination of all 3 medications has not been reported previously to our knowledge. In this observational study, we found that the prestroke use of ACEI was independently associated with improving the functional outcome of patients at discharge, as measured by the BI scale. Using multiple logistic regression to control other factors that might affect the functional status of stroke patients, our results showed that previous treatment with ACEI either alone or combined with AP and/or statin was associated with 2 increased odds of better functional outcome at discharge (95% CI, 1.28Y3.11; P = 0.002). Furthermore, previous studies supported the positive effect of previous ACEI use on ischemic stroke outcomes; they concluded that patients treated with ACEI before stroke had less severe stroke, less mortality rate, less cognitive impairment, less weakness, and less dysarthria/dysphasia after the attack than did patients not treated with ACEI. 4, 36, 37 The benefits of ACEI on ischemic stroke morbidity and mortality could readily be described by lowering blood pressure mechanism. Reduction in the synthesis of the potent vasoconstrictor angiotensin II and decreasing the degradation of bradykinin within the renin-angiotensin system are considered the main mechanism of action of ACEI. 3 Neuroprotective effects via the blocking of angiotensin IIYmediated endothelial dysfunction, lipid peroxidation, and subsequent oxidative stress, as well as vascular smooth muscle intracellular calcium accumulation and hypertrophy, are additional mechanisms of ACEI that may describe their beneficial effects on stroke severity and outcomes. 6, 38 Regarding the functional outcome at discharge among patients on previous ACEI either alone or in combination with AP and/or statin, by using ACEI alone as the reference it has been shown that there was no significant difference among ACEI alone, ACEI + AP, ACEI + statin, or ACEI + AP + statin combinations on the BI score at discharge (P = 0.852). Nevertheless, our results should take into consideration the fact that patients on a combination of 3 drugs may have more cardiovascular risk factors.
In a previous study by Kumar et al, 24 they concluded that prestroke use of AP + ACEI + statin may result in additive reduction in stroke severity and the volume of ischemic tissue compared with those on AP alone or patients on no previous medications. This result may support the beneficial effect of previous use of ACEI in improving ischemic stroke outcomes. However, the same previous study found that a larger but insignificant percentage of patients on triple therapy had better functional status upon discharge than patients on AP alone as measured by the modified Rankin Scale. 24 Moreover, another study found that the combination therapy of antihypertensive, AP, and statins was associated with a better functional outcome after stroke. 39 However, they found that previous treatment with any of these medications, either alone or in combination, was not a significant predictor of stroke severity. On the other hand, this study differed from our study as it included all antihypertensive agents in combination with AP and statin. 39 In the current study, the independent variables associated with good functional outcome were younger age, first-ever attack, LACI or POCI stroke subtype, minor GCS score, and previous use of ACEI either alone or in combination with AP and/or statin.
Although previous findings have suggested that previous transient ischemic stroke may raise the threshold of brain tissue to subsequent ischemic insults that result in smaller infarcts and better recovery, 40 in our study first stroke attack is independently associated with improved functional outcome; this may be as a result of a lower number of comorbid diseases among that group of patients or due to the induction of ischemic tolerance among these patients caused by prestroke AP treatment. 40 In addition, the current study found that a lower GCS value is an independent factor associated with good functional outcome. Usually, patients admitted with minor GCS score have LACI, the least severe stroke class. In addition, a previous study showed that an increase in GCS score was correlated with improved functional outcome as measured by independence in activities of daily living, as well as being a predictor of survival after stroke. 41 Having a diagnosis of LACI or POCI stroke subtype has been significantly associated with favorable outcome. On the other hand, patients with a diagnosis of TACI were discharged with significantly worse outcomes, illustrating that OCSP classification may be correlated with stroke severity, with TACI classes having the worst prognosis. 21 Although this study is the first to compare the impact of the combined medication regimens of ACEI, AP, and statin on ischemic stroke outcome, there were some limitations. First, this was a single hospitalYbased study. Second, because of the retrospective nature of the study, we depend on patients' adherence to previous medication as reported in the medical records by the physician or the pharmacist through asking the patients or their families. Third, the National Institutes of Health Stroke Scale was not measured upon patient's admission; thus, we did not include it in the variables studied; however, previous studies showed that OCSP classification is an indicator of stroke severity, with TACI being the most severe subtype.
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CONCLUSIONS
Our results suggest that previous treatment with ACEI either alone or combined with AP and/or statin was associated with a better functional outcome after ischemic stroke, as measured by BI scores. Moreover, previous use of ACEI in combination with AP and/or statin did not significantly differ from previous use of ACEI alone in their effect on functional stroke outcome. This study provides a potential rationale for optimizing the use of ACEI among individuals at risk of developing ischemic stroke. These findings need to be prospectively validated in randomized studies, to confirm the effectiveness of these preventative medications on clinical outcomes after stroke.
